OptimizeRx Corporation
OPRX
$6.60
$0.172.64%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 109.43M | 109.51M | 104.75M | 94.37M | 92.13M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 109.43M | 109.51M | 104.75M | 94.37M | 92.13M |
| Cost of Revenue | 35.83M | 37.99M | 37.30M | 33.85M | 32.75M |
| Gross Profit | 73.60M | 71.52M | 67.45M | 60.52M | 59.38M |
| SG&A Expenses | 57.21M | 60.17M | 59.21M | 59.22M | 61.02M |
| Depreciation & Amortization | 4.33M | 4.34M | 4.36M | 4.36M | 4.33M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 97.37M | 102.50M | 100.87M | 97.42M | 98.10M |
| Operating Income | 12.06M | 7.00M | 3.88M | -3.06M | -5.97M |
| Income Before Tax | 6.95M | 1.69M | -9.30M | -16.11M | -19.38M |
| Income Tax Expenses | 1.82M | 1.65M | 565.00K | -704.00K | 725.00K |
| Earnings from Continuing Operations | 5.13 | 0.03 | -9.87 | -15.41 | -20.11 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.13M | 34.00K | -9.87M | -15.41M | -20.11M |
| EBIT | 12.06M | 7.00M | 3.88M | -3.06M | -5.97M |
| EBITDA | 16.39M | 11.33M | 8.20M | 1.27M | -1.65M |
| EPS Basic | 0.27 | 0.00 | -0.54 | -0.84 | -1.10 |
| Normalized Basic EPS | 0.24 | 0.07 | -0.05 | -0.29 | -0.40 |
| EPS Diluted | 0.25 | 0.00 | -0.54 | -0.84 | -1.10 |
| Normalized Diluted EPS | 0.23 | 0.06 | -0.06 | -0.29 | -0.40 |
| Average Basic Shares Outstanding | 74.22M | 73.98M | 73.72M | 73.47M | 73.17M |
| Average Diluted Shares Outstanding | 76.33M | 75.36M | 74.23M | 73.47M | 73.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |